BTIG analyst Gregory Lewis maintained a Buy rating on Blue Bird (BLBD – Research Report) today and set a price target of $45.00. The company’s ...

BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

BTIG analyst Mark Massaro notes that earlier today, a short report was published on GeneDx (WGS), which alleges wholesale reimbursement fraud ...

While value offerings are helping improve sales, some franchisees have yet to fully recover their visits and sales comps as ...

The deal priced below last closing price of $8.44. BTIG is acting as lead book running manager for the offering. Published first on TheFly – the ...

BTIG Research lowered shares of IQVIA (NYSE:IQV – Free Report) from a buy rating to a neutral rating in a research report report published on Monday morning, Marketbeat.com reports. Several other ...

BTIG Research has recently reduced Ginkgo Bioworks Holdings Inc (DNA) stock to Sell rating, as announced on May 15, 2024, according to Finviz. Earlier, on May 10, 2024, William Blair had reduced the ...

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, ...

BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and ...

Treace provides technology that facilitates Lapiplasty bunion surgery and related midfoot deformities. The company recently ...

Performant Healthcare, Inc. (Nasdaq: PHLT) ("Performant"), a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, announced today that it will ...